Affiliation:
1. Department of Pharmacology and Toxicology Virginia Commonwealth University Richmond Virginia USA
2. The Ohio Attorney General's Center for the Future of Forensic Science Bowling Green State University Bowling Green Ohio USA
Abstract
AbstractHere, we present recent studies suggesting that specific DRD3 single nucleotide polymorphisms (SNPs, e.g. rs324029 and rs2654754) might serve as prognostic biomarkers for opioid use disorder (OUD). Additionally, preclinical studies with novel dopamine 3 receptor (D3R) partial agonists and antagonists have been evaluated as candidate OUD therapeutics and have shown a reduced risk of cardiovascular toxicity compared with the original D3R antagonist. From these findings, we argue that DRD3 SNPs could serve as a diagnostic tool for assessing OUD risk and that more research is warranted examining the D3R as a safe and effective therapeutic target for treating OUD.
Funder
National Institutes of Health
Ohio Attorney General's Office
National Institute on Drug Abuse
Subject
Psychiatry and Mental health,Pharmacology,Medicine (miscellaneous)